

ORIGINAL PAPER

doi: 10.5455/medarch.2018.72.164-169

MED ARCH. 2018 JUN; 72(3): 164-169

RECEIVED: MAR 10, 2018 | ACCEPTED: MAY 15, 2018

¹Department of Biology, Faculty of Science, University of Sarajevo, Bosnia and Herzegovina

²Center of Genetics, Medical Faculty, University of Sarajevo, Bosnia and Herzegovina

Corresponding author: Prof Hilada Nefic, PhD. Department of Biology, Faculty of Science, University of Sarajevo. Zmaja od Bosne 33-35, Sarajevo 71000, Bosnia and Herzegovina. ORCID ID: <http://www.orcid.org/0000-0002-7774-5743>. Phone: +387 33 723 717; Fax: ++387 33 649 359. E-mails: hnefic@pmf.unsa.ba, hnefic@gmail.com

The Frequency of the 677C>T and 1298A>C Polymorphisms in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in the Population

Hilada Nefic¹, Mirela Mackic-Djurovic², Izet Eminovic¹

ABSTRACT

Background: The gene for 5,10-methylenetetrahydrofolate reductase (NAD(P)H) or *MTHFR* gene encodes protein methylenetetrahydrofolate reductase (MTHFR), an enzyme important in folate metabolism. **Aim:** The aim of this study was to determine the frequencies of 677C>T and 1298A>C polymorphisms in the *MTHFR* gene of healthy subjects from the population. **Material and methods:** The blood samples were collected from 164 unrelated and healthy donors from population consisted of 98 females and 66 males. Both the *MTHFR* 677C>T and 1298A>C single nucleotide polymorphisms (SNPs) were analyzed by Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Linkage disequilibrium (LD) between pair of SNPs was calculated through Haploview analysis. **Results:** The frequency of *MTHFR* 677T allele in the population (32.62%) was in agreement with the frequency of this allele in most other populations, however, the frequency of *MTHFR* 1298C allele (38.41%) was higher than that reported for most other populations in the world. Haploview analysis showed a relatively strong LD between 677C>T and 1298A>C SNPs with *D'* values of 0.87. **Conclusion:** Regarding the two *MTHFR* polymorphisms, three of the nine combined genotypes were present in 87.2% of the population. 33.54% subjects were complex heterozygous (677CT/1298AC genotype), 34.15% subjects had 677CC/1298AC and 19.51% of 677CT/1298AA genotype. The subjects with 677TT genotype had a 1298AA or 1298AC genotype while subjects with 1298CC genotype had only 677CC genotype. The subjects with 677CC/1298AA genotype were only 3.05%. We were not found triple 677CT/1298CC and quadruple 677TT/1298CC mutation suggesting decreased viability of embryos with increased numbers of mutant alleles. **Keywords:** *MTHFR* gene, SNPs, 677C>T, 1298A>C, polymorphisms, PCR-RFLP.

1. INTRODUCTION

The gene for 5,10-methylenetetrahydrofolate reductase (NAD(P)H) or *MTHFR* gene (OMIM: 607093) is located on the short (p) arm of chromosome 1 (cytogenetic location: 1p36.22). It ranges from 11,785,729 base pairs (bp) to 11,806,102 bp (GRCh38, NCBI) and its total length is 20,374 bp. It consists of 11 exons. *MTHFR* gene encodes an enzyme methylenetetrahydrofolate reductase (MTHFR; EC 1.5.1.20) made from 656 amino acids and a molecular weight is 74,597 Da. Methylenetetrahydrofolate reductase is important for a chemical reaction involving forms of the vitamin folate (vitamin B9). Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-methylenetetrahydrofolate (5,10-MTHF) to 5-methyltetrahydrofolate (5-MTHF). This reaction is required for the re-methylation of

amino acid homocysteine (Hcy) to methionine.

Although a number of mutations were described, 677C>T (rs1801133) and 1298A>C (rs1801131) SNPs (single nucleotide polymorphisms) are the two most common mutations in the *MTHFR* gene. Many of the *MTHFR* gene polymorphisms alter or decrease the activity of methylenetetrahydrofolate reductase, leading to an increase of homocysteine in the blood. Decreased folate and increased plasma Hcy levels are associated with a variety of common conditions such as cardiovascular disease, neural tube defects, cleft lip/palate, hypertension, preeclampsia, thrombosis, osteoporosis, dementia, Alzheimer's disease, Down syndrome, certain types of cancer, glaucoma, pregnancy complications, migraine, epilepsy, depression and schizophrenia.

© 2018 Hilada Nefic, Mirela Mackic-Djurovic, Izet Eminovic

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Polymorphism 677C>T (OMIM: 607093.0003) in the coding region of the *MTHFR* gene (position: 11,796,321) was described by Frosst (1). The replacement of cytosine with thymine is a point mutation of the transition type in exon 4 of this gene (c.788C>T) which alanine changes to valine (p.Ala222Val or A222V) in the N-terminal catalytic domain of MTHFR protein and is responsible for the synthesis of a thermolabile form of MTHFR with reduced enzymatic activity. 677C>T polymorphism is relatively common and has been studied for a long time.

Another mutation that often occurs in the *MTHFR* gene 1298A>C (OMIM: 607093.0004) is the first time described by van der Put (2). 1298AC transversion is located in exon 7 (position: 11,794,419) that leads to the replacement of adenine with cytosine (c.1286A>C) resulting in transfer glutamic acid to alanine (p.Glu429Ala or E429A) within the C-terminal regulatory domain of the protein. The 1298AC mutation is associated with decreased MTHFR activity that is more pronounced in the homozygous than heterozygous state.

The frequency of the *MTHFR* 677C>T and 1298A>C polymorphisms varies in different geographical regions of the world and among different ethnic groups. Although the frequency of MTHFR 677C>T polymorphism has been established (3, 4), *MTHFR* 1298A>C polymorphism has not been investigated in Bosnia and Herzegovina so far. The aim of this study was to determine the frequency of 677C>T and 1298A>C polymorphisms in the methylenetetrahydrofolate reductase (*MTHFR*) gene in peripheral blood samples of healthy subjects from the population using the polymerase chain reaction (PCR) and the restriction fragment length polymorphism (RFLP) method. Subsequently, we compared the obtained frequencies of minor alleles (MAF) with the frequencies of these polymorphisms in some other populations of the world.

2. MATERIALS AND METHODS

Samples Collection

The blood samples were collected from 164 unrelated and healthy donors from population consisted of 98 females and 66 males between 17 and 79 years of age (Table 1). Blood samples (3 ml) were taken and collected into tubes with EDTA. All individuals who participated in this study belonged to Caucasians from different regions of Bosnia and Herzegovina between 2011 and 2015. All the subjects included in this analysis gave written informed consent to participate in the study. The study was approved by the Ethics Committee of the Faculty of Science on University of Sarajevo (01/01-556/2-2018).

DNA isolation and detection of MTHFR gene mutations

After genomic DNA was extracted from whole peripheral blood according to a previously described method proposed by Miller et al. (5) with several small modifications, the *MTHFR* 677C>T and 1298A>C polymorphisms were analyzed using the PCR-RFLP method. A fragment of 198 bp containing the polymorphic site in the exon 4 of *MTHFR* gene was amplified by PCR on a thermal cycler (Eppendorf Mastercycler gradient,

Hamburg, Germany) in 0.2-ml thin-walled tubes using previously described couples of primers for 677C>T: 5'-TGAAGGAGAAGGTGTCTGCGGGA -3' as the forward and 5'-AGGACGGTGCGGTGAGAGTG -3' as the reverse primer (1) while a fragment of 163 bp containing the polymorphic site in the exon 7 of *MTHFR* gene was amplified using 5'-CTTTGGGGAGCTGAAGGACTACTAC -3' as the forward and 5'-CACTTTGTGAC-CATTCGGTTTG -3' as the reverse primer (2).

PCR amplifications were performed in 25 µl reaction mixture contained 50–100 ng of template DNA, 1x PCR buffer (10x PCR Buffer without MgCl₂; Sigma-Aldrich, USA), 1.5 mM of magnesium chloride solution (25 mM MgCl₂; Sigma-Aldrich, USA), 0.2 mM of deoxynucleotide (dNTP) solution mix (equimolar solution of 10 mM dATP, 10 mM dCTP, 10 mM dGTP, 10 mM TTP; New England BioLabs, USA), 0.2 µM of each primer (Sigma-Aldrich, USA) and 1.25 U of *Taq* DNA Polymerase (*Taq* DNA Polymerase; Sigma-Aldrich, USA). An initial denaturation step of 5 minutes at 95 °C was followed by 37 cycles for 30 seconds at 95 °C, 30 seconds at 61 °C and 30 seconds at 72 °C, and a 10-minute elongation step at 72 °C at the end of the cycles. The amplification products were electrophoresed in ethidium bromide-stained 2% agarose gels.

After gel electrophoresis, each remaining PCR product was digested with the restriction endonucleases *Hinf* I and *Mbo*II (New England BioLabs, USA), separately. The digestion reactions contained: 10 µl of PCR product (0.1–0.5 µg of DNA), 2.5 µl of buffer (10x NEBuffer Cut Smart, supplied with enzyme) 0.5 µl of restriction enzyme (concentration: 10U/µl) and 12 µl of nuclease-free water. Restriction analysis was performed for 4 hours at 37 °C. The digestion products were separated on ethidium bromide-stained 3% agarose gels at 70 V and visualized under ultraviolet light.

Regarding the 677C>T SNP, since mutation creates a *Hinf* I restriction site (5'-G|ANTC-3'), the amplicon of the wild-type allele (198 bp) is not cut, while the mutant one is cut into two fragments of 175 and 23 bp respectively. In agarose gel electrophoresis it is possible to see the 198 and 175 bp fragments, the 23-bp fragment is not retained in the gel. Nevertheless, concerning the 1298A>C SNP, since mutation abolishes a restriction site for *Mbo*II enzyme (5'-GAAGAN8-3'), the amplicon (163 bp) of the mutated allele will be cut into four (84, 31, 30 and 18 pb) instead of five fragments (56, 31, 30, 28 and 18 bp) as a wild type allele. In agarose gel electrophoresis it is possible to see the 84 and 56 bp fragments and fragments of 30, 31 and 28 bp as one band.

Statistical Analysis

Allelic and genotypic frequencies were calculated by the gene counting method. The chi-square (χ^2) test was used to evaluate the Hardy-Weinberg equilibrium for the distribution of genotypes of subjects and to determine differences in the distribution of genotypes and allele frequencies between males and females. Linkage disequilibrium (LD) analysis was performed using the Haploview software version 4.2 (Daly Lab at the Broad Institute, Cambridge, USA). Comparisons of SNP fre-

The Frequency of the 677C>T and 1298A>C Polymorphisms

	MTHFR 677C>T polymorphism				χ^2 test	MTHFR 1298A>C polymorphism				χ^2 test
	Genotype/Allele	Total n (%)	Male n (%)	Female n (%)		Genotype/Allele	Total n (%)	Male n (%)	Female n (%)	
Sample size		164 (100)	66 (100)	98 (100)			164 (100)	66 (100)	98 (100)	
Age (mean \pm SD)		34.85 \pm 14.58	34.59 \pm 15.10	35.03 \pm 14.30			34.85 \pm 14.58	34.59 \pm 15.10	35.03 \pm 14.30	
Genotype frequency	CC	67 (40.85)	28 (42.42)	39 (39.8)	$\chi^2 = 1.817$ P = 0.4030	AA	44 (26.83)	19 (28.79)	25 (25.51)	$\chi^2 = 2.202$ P = 0.3325
	CT	87 (53.05)	36 (54.55)	51 (52.04)		AC	114 (69.51)	43 (65.15)	71 (72.45)	
	TT	10 (6.1)	2 (3.03)	8 (8.16)		CC	6 (3.66)	4 (6.06)	2 (2.04)	
HWE	χ^2	7.01022	0.08635	2.40155		χ^2	36.0918	9.23188	27.88707	
	P value	0.00810*	0.76885	0.12121		P value	0.00000*	0.00237*	0.00000*	
Allele frequency	C	221 (67.38)	92 (69.7)	129 (65.82)	$\chi^2 = 0.378$ P = 0.5385	A	202 (61.59)	81 (61.36)	121 (61.73)	$\chi^2 = 0.00230$ P = 0.9617
	T	107 (32.62)	40 (30.3)	67 (34.18)		C	126 (38.41)	51 (38.64)	75 (38.27)	
	Total	328 (100)	132 (100)	196 (100)		Total	328 (100)	132 (100)	196 (100)	

Table 1. Genotype and allele frequencies of MTHFR gene polymorphisms in the population. *Statistically significant.

Study	Country	Sample size (n)	Distribution of 677C>T MTHFR genotype (n)			HWE P	Frequency of 677C>T MTHFR alleles			
			CC	CT	TT		T, n (%)	95% CI	χ^2	P
Present study		164	67	87	10	0.008*	107 (32.62)			
Biseli et al, 2008 (6)	Brazil	194	100	77	17	0.69	111 (28.61)	-2.941% - 10.98%	1.167	P = 0.2800
Boduroglu et al, 2004 (7)	Turkey	91	58	30	3	0.71	36 (19.78)	4.58% - 20.542%	8.939	P = 0.0028*
Balta et al, 2003 (8)	Turkey	185	90	87	8	0.02*	103 (27.84)	-2.233% - 11.789%	1.668	P = 0.1965
Basol et al, 2016 (9)	Turkey	126	86	35	5	0.55	45 (17.86)	7.442% - 21.779%	15.300	P = 0.0001*
Thirumaran et al, 2005 (10)	Germany	1448	600	681	167	0.21	1015 (35.05)	-3.211% - 7.78%	0.663	P = 0.4154
Kurzweily, 2010 (11)	Germany	212	96	96	20	0.57	136 (32.08)	-6.341% - 7.494%	0.00615	P = 0.9375
Lightfoot et al, 2005 (12)	UK	755	356	316	83	0.31	482 (31.92)	-4.898% - 6.557%	0.0327	P = 0.8564
Chango et al, 2005 (13)	France	119	49	58	12	0.39	82 (34.45)	-6.234% - 9.991%	0.134	P = 0.7148
Coppede et al, 2009 (14)	Italy	113	40	55	18	0.90	91 (40.26)	-0.75% - 16.036%	3.076	P = 0.0794
Kokotas et al, 2009 (15)	Denmark	1084	545	449	90	0.85	629 (29.01)	-1.806% - 9.304%	1.616	P = 0.2036
Martinez-Friaz, 2008 (16)	Spain	188	76	85	27	0.68	139 (36.97)	-2.912% - 11.526%	1.273	P = 0.2592
Meguid et al, 2008 (17)	Egypt	48	33	12	3	0.21	18 (18.75)	3.328% - 22.884%	6.221	P = 0.0126*
O'Leary et al, 2002 (18)	Ireland	192	90	84	18	0.80	120 (31.25)	-5.664% - 8.442%	0.0963	P = 0.7563
Wang et al, 2008 (19)	China	70	36	29	5	0.79	39 (27.86)	-4.871% - 13.771%	0.826	P = 0.3635
Muthuswamy et al, 2016 (20)	India	110	80	30	0	0.09	30 (13.64)	11.693% - 25.821%	24.297	P < 0.0001*
Jusić-Karić et al, 2016 (3)	BiH	207	91	92	24	0.92	140 (33.82)	-5.834% - 8.153%	0.0708	P = 0.7902
Mahmutbegović et al, 2017 (4)	BiH	154	71	74	9	0.07	92 (29.87)	-4.679% - 10.124%	0.438	P = 0.5080
Damjanovic et al, 2010 (21)	Serbia	412	163	190	59	0.76	308 (37.38)	-1.547% - 10.849%	2.105	P = 0.1469
Alfirevic et al, 2010 (22)	Croatia	104	37	59	8	0.02*	75 (36.06)	-5.008% - 12.013%	0.527	P = 0.4679
Petra et al, 2007 (23)	Slovenia	258	112	110	36	0.29	182 (35.27)	-4.118% - 9.278%	0.513	P = 0.4737
Li et al, 2013 (24)	USA	564	236	246	82	0.17	410 (36.35)	-2.329% - 9.544%	1.385	P = 0.2392
Lincz et al, 2003 (25)	Australia	299	145	133	21	0.19	175 (29.26)	-2.975% - 9.833%	0.976	P = 0.3232

Table 2. Distribution of genotypes and allele frequencies of 677C>T MTHFR gene observed in this study compared with those found in other populations. *Statistically significant.

quencies between population and other ethnic populations were done using a chi-square test with significance level of 0.05 and 95% confidence intervals (95% CI) using the MedCalc statistical software package version 12.5.0.0 (Ostend, Belgium).

3. RESULTS

Table 1 gives frequencies of genotypes and alleles of the *MTHFR* 677C>T and 1298A>C polymorphisms. The frequencies of 677CC, CT and TT genotypes among subjects from the population were 40.85%, 53.05% and 6.1%, respectively resulting in a T allele frequency of 32.62%. The genotype distribution for males and females was in

Study	Country	Sample size (n)	Distribution of 1298A>C MTHFR genotype (n)			HWE P	Frequency of 1298A>C MTHFR alleles			P
			AA	AC	CC		C, n (%)	95% CI	χ^2	
Present study		164	44	114	6	0.00*	126 (38.41)			
Biseli et al, 2008 (6)	Brazil	194	108	74	12	0.89	98 (25.26)	6.119% - 20.102%	13.692	P = 0.0002*
Boduroglu et al, 2004 (7)	Turkey	91	21	60	10	0.00*	80 (43.96)	-3.618% - 14.756%	1.276	P = 0.2587
Basol et al, 2016 (9)	Turkey	126	74	48	4	0.25	56 (22.22)	8.455% - 23.609%	16.605	P < 0.0001*
Niclot et al, 2006 (26)	France	198	102	81	15	0.84	111 (28.03)	3.301% - 17.407%	8.314	P = 0.0039*
Gemmati et al, 2004 (27)	Italy	257	126	110	21	0.66	152 (29.57)	2.115% - 15.593%	6.681	P = 0.0097*
De Re et al, 2010 (28)	Italy	96	33	54	9	0.05*	72 (37.50)	-8.072% - 9.709%	0.0127	P = 0.9103
Martinez-Friaz, 2008 (16)	Spain	188	91	78	19	0.70	116 (30.85)	0.322% - 14.754%	4.110	P = 0.0426*
Meguid et al, 2008 (17)	Egypt	48	18	29	1	0.00*	31 (32.29)	-5.472% - 16.829%	0.945	P = 0.3310
Muthuswamy et al, 2016 (20)	India	110	53	50	7	0.28	64 (29.09)	0.952% - 17.394%	4.647	P = 0.0311*
Berglund et al, 2009 (29)	Sweden	449	214	196	39	0.53	274 (30.51)	1.754% - 14.166%	6.467	P = 0.0110*
Kim et al, 2005 (30)	South Korea	445	308	129	8	0.19	145 (16.29)	16.228% - 28.109%	66.523	P < 0.0001*
Kurzweily, 2010 (11)	Germany	212	106	89	17	0.78	123 (29.01)	2.407% - 16.369%	6.960	P = 0.0083*
Weiner, 2011 (31)	Russia	503	232	215	56	0.56	327 (32.50)	-0.168% - 12.124%	3.594	P = 0.0580
Li et al, 2013 (24)	USA	574	265	250	59	0.99	368 (32.06)	0.371% - 12.476%	4.339	P = 0.0373*
Lincz et al, 2003 (25)	Australia	294	124	139	31	0.38	201 (34.18)	-2.397% - 10.934%	1.462	P = 0.2266
Lightfoot et al, 2005 (12)	UK	755	347	331	77	0.88	485 (32.12)	0.472% - 12.273%	4.525	P = 0.0334*

Table 3. Distribution of genotypes and allele frequencies of 1298A>C MTHFR gene observed in this study compared with those found in other populations. *Statistically significant.

the Hardy-Weinberg equilibrium. The frequencies of 1298AA homozygotes, AC heterozygotes and CC homozygote were 26.83%, 69.51% and 3.66%, respectively. The 1298A>C genotype distribution deviated from the expected Hardy-Weinberg distribution. The overall C allele frequency was 38.41%.

It was found that there was no statistically significant difference in the distribution of genotypes for 677C>T polymorphism between males and females (P = 0.4030). The frequency of 677T allele was higher in females (34.18%) than in males (30.3%) but this difference was not statistically significant according to chi-square test (P = 0.5385). Similarly, there were no significant differences in the distribution of genotypes (P = 0.3325) and allele frequencies (P = 0.9617) for 1298A>C polymorphism between males and females (Table 1).

Regarding the two common MTHFR polymorphisms, three of the nine combined genotypes were present in 87.2% of the population. Fifty five subjects (33.54%) were heterozygous for both MTHFR polymorphisms (677CT/1298AC genotype). We detected 56 individuals (34.15%) with the 677CC/1298AC genotype and 32 (19.51%) with the 677CT/1298AA genotype. The combined genotypes 677TT/1298AA (4.27%), 677CC/1298CC (3.66%) and 677CC/1298AA (3.05%) as well as the triple mutation 677TT/1298AC (1.83%) represent total 12.8%. The subjects with triple 677CT/1298CC and quadruple 677TT/1298CC mutations were not found.

Haploview analysis showed a relatively strong LD between MTHFR 677C>T and 1298A>C SNPs with D' values of 0.87 and the correlation r² of 0.23.

The frequency of MTHFR 677T allele in the population (32.62%) was in agreement with the frequency of this allele in most other populations in the world (Brazil, Turkey, Germany, UK, France, Italy, Denmark, Spain, Ireland, China, Bosnia and Herzegovina, Serbia, Croatia, Slovenia, USA and Australia) but significantly different

from the frequency of 677T allele in the population of Turkey for two samples (P = 0.0028 and P = 0.0001), the samples from Egypt (P = 0.0126) and India (P < 0.0001) (Table 2). However, the frequency of MTHFR 1298C allele in the population (38.41%) was much higher (except for one population from Turkey: 43.96%) than that reported for other populations in the world (Brazil, Turkey, France, Italy, Spain, Egypt, India, Sweden, South Korea, Germany, Russia, USA, Australia and UK). These differences were statistically significant (P < 0.05) except for population from Turkey (one sample), Italy (one sample), Egypt, Russia and Australia (Table 3).

4. DISCUSSION

MTHFR 677T and 1298C allele frequencies differ between populations. The frequency of MTHFR 677T allele in the population (32.62%) observed in this study is consistent with results of previous studies (3, 4) as well as with the frequency of allele in most other populations, however, the frequency of MTHFR 1298C allele (38.41%) was higher than frequency of this allele in the most other populations in the world. These differences were statistically significant (P < 0.05). We found that there were no statistically significant differences in the distribution of genotypes and allele frequencies for MTHFR 677C>T and 1298A>C polymorphisms between males and females.

After analysis of combined genotypes for these two polymorphisms we observed that the most frequent subjects (34.15%) were homozygous for 677C allele and heterozygous of the 1298 locus (677CC/1298AC genotype). But, those who were complex heterozygous for 677 and 1298 locus (677CT/1298AC genotype) were 33.54%. Subjects who were heterozygous for the 677 locus and homozygous for 1298C allele (677CT/1298AA genotype) were 19.51%. The subjects with 677TT genotype had a 1298AA (4.27%) or 1298AC genotype (1.83%) while sub-

jects with 1298CC genotype had only 677CC genotype (3.66%). These genotypes represent 12.8%. Just three subjects had a triple 677TT/1298AC genotype, probably as result of recombination between the two ancestor genotypes (most likely 677CT/1298AC genotype). These results suggest that 677T allele is linked with the A allele of 1298 locus and 1298C allele is associated with C allele of locus 677. Only 3.05% subjects were heterozygous for both MTHFR wild-type alleles (677CC/1298AA genotype). The triple 677CT/1298CC and quadruple 677TT/1298CC mutation has not been found suggestion decreased viability of embryos with increased numbers of mutant alleles.

Combined genotypes which contain three or four mutant alleles were not detected or detected several implying linkage disequilibrium between two polymorphisms. The pattern of LD in the MTHFR gene showed a relatively strong LD between 677C>T and 1298A>C SNPs with D' values of 0.87 and the correlation r^2 of 0.23. The examples of LD observed in natural populations are the result of a complex interaction between genetic factors and the demographic history of the population. Particularly, recombination shows a significant role in determining the patterns of LD in a population.

5. CONCLUSIONS

The frequency of MTHFR 677T allele in the population (32.62%) was in agreement with the frequency of this allele in most other populations, however, the frequency of MTHFR 1298C allele (38.41%) was higher than frequency of this allele in the most other populations of the world.

- Conflict of interest statement: The authors declare no conflict of interest.

REFERENCES

1. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet.* 1995; 10(1): 111-113. doi:10.1038/ng0595-111.
2. Van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet.* 1998; 62(5): 1044-1051.
3. Jusić-Karić A, Terzić R, Jerkić Z, Avdić A, Pođanin M. Frequency and association of 1691 (G>A) FVL, 20210 (G>A) PT and 677 (C>T) MTHFR with deep vein thrombosis in the population of Bosnia and Herzegovina. *Balkan Journal of Medical Genetics: BJMG.* 2016; 19(1): 43-50. doi:10.1515/bjmg-2016-0006.
4. Mahmutbegović E, Marjanović D, Medjedović E, Mahmutbegović N, Dogan S, Valjevac A, et al. Prevalence of F5 1691G>A, F2 20210G>A, and MTHFR 677C>T polymorphisms in Bosnian women with pregnancy loss. *Bosnian Journal of Basic Medical Sciences.* 2017; 17(4): 309-314. doi:10.17305/bjbm.2017.1954.
5. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acid Research.* 1988; 16(3): 1215.
6. Biselli JM, Goloni-Bertollo EM, Zampieri BL, Haddad R, Eberlin MN, Pavarino-Bertelli EC. Genetic polymorphisms involved in folate metabolism and elevated plasma concentrations of homocysteine: maternal risk factors for Down syndrome in Brazil. *Genet Mol Res.* 2008; 7(1): 33-42.
7. Boduroğlu K, Alanay Y, Koldan B, Tunçbilek E. Methylenetetrahydrofolate reductase enzyme polymorphisms as maternal risk for Down syndrome among Turkish women. *Am J Med Genet A.* 2004; 127A(1): 5-10. doi: 10.1002/ajmg.a.20432.
8. Balta G, Yuksek N, Ozyurek E, Ertem U, Hicsonmez G, Altay C, et al. Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 Genotypes in Childhood Acute Leukemia. *Am J Hematol.* 2003; 73: 154-160.
9. Basol N, Karakus N, Savas AY, Kaya I, Karakus K, Yigit S. The importance of MTHFR C677T/A1298C combined polymorphisms in pulmonary embolism in Turkish population. *Medicina.* 2016; 52: 35-40.
10. Thirumaran RK, Gast A, Flohr T, Burwinkel B, Bartram C, Hemminki K, et al. MTHFR genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. *Blood.* 2005; 106(7): 2591-2592. doi: 10.1182/blood-2005-04-1719.
11. Kurzwelly D, Knop S, Guenther M, Loeffler J, Korfel A, Thiel E, et al. Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population. *J Neurooncol.* 2010; 100(2): 187-192. doi: 10.1007/s11060-010-0154-4.
12. Lightfoot TJ, Skibola CF, Willett EV, Skibola DR, Allan JM, Coppede F, et al. Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. *Cancer Epidemiol Biomarkers Prev* 2005; 14(12): 2999-3003. doi: 10.1158/1055-9965.EPI-05-0515.
13. Chango A, Fillon-Emery N, Mircher C, Bléhaut H, Lambert D, Herbeth B, et al. No association between common polymorphisms in genes of folate and homocysteine metabolism and the risk of Down's syndrome among French mothers. *Br J Nutr.* 2005; 94(2): 166-169.
14. Coppède F, Migheli F, Bargagna S, Siciliano G, Antonucci I, Stuppia L, et al. Association of maternal polymorphisms in folate metabolizing genes with chromosome damage and risk of Down syndrome offspring. *Neurosci Lett.* 2009; 449(1): 15-19. doi: 10.1016/j.neulet.2008.10.074.
15. Kokotas H, Grigoriadou M, Mikkelsen M, Giannoulia-Karantana A, Petersen MB. Investigating the impact of the Down syndrome related common MTHFR 677C>T polymorphism in the Danish population. *Dis Markers.* 2009; 27(6): 279-285. doi: 10.3233/DMA-2009-0673.
16. Martinez-Frias ML. The biochemical structure and function of methylenetetrahydrofolate reductase provide the rationale to interpret the epidemiological results on the risk for infants with Down syndrome. *Am J Med Genet A.* 2008; 146A(11): 1477-1482. doi: 10.1002/ajmg.a.32308.
17. Meguid NA, Dardir AA, Khass M, Hossieny LE, Ezzat A, El Awady MK. MTHFR genetic polymorphism as a risk factor in Egyptian mothers with Down syndrome children. *Dis Markers.* 2008; 24(1): 19-26.
18. O'Leary VB, Parle-McDermott A, Molloy AM, Kirke PN, Johnson Z, Conley M, et al. MTRR and MTHFR polymorphism: link to Down syndrome? *Am J Med Genet.* 2002; 107(2): 151-155.

19. Wang S, Qiao F, Feng L, Lv J. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome in China. *J Zhejiang Univ Sci B*. 2008; 9(2): 93-99. doi: 10.1631/jzus.B0710599.
20. Muthuswamy S, Agarwal S. Do the MTHFR gene polymorphism and Down syndrome pregnancy association stands true? A case-control study of Indian population and meta-analysis. *The Egyptian Journal of Medical Human Genetics*. 2016; 17(1): 87-97. doi: 10.1016/j.ejmhg.2015.08.003.
21. Damnjanovic T, Milicevic R, Novkovic T, Jovicic O, Bunjevacki V, Jekic B, et al. Association between the methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia in Serbian children. *J Pediatr Hematol Oncol*. 2010; 32(4): e148-e150. doi: 10.1097/MPH.0b013e3181cbd252.
22. Alfirevic Z, Simundic AM, Nikolac N, Sobocan N, Alfirevic I, Stefanovic M, et al. Frequency of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case-control study. *Biochemia Medica*. 2010; 20(2): 229-235. doi:10.11613/BM.2010.028.
23. Petra BG, Janez J, Vita D. Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children. *Leuk Lymphoma*. 2007; 48: 786-792. doi:10.1080/10428190601187711.
24. Li Q, Lan Q, Zhang Y, Bassig BA, Holford TR, Leaderer B, et al. Role of One-carbon Metabolizing Pathway Genes and Gene-Nutrient Interaction in the Risk of Non-Hodgkin Lymphoma. *Cancer Causes Control*. 2013; 24(10): 1875-1884. doi: 10.1007/s10552-013-0264-3.
25. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. *Br J Haematol*. 2003; 120(6): 1051-1054. doi: 10.1046/j.1365-2141.2003.04220.x.
26. Niclot S, Pruvot Q, Besson C, Savoy D, Macintyre E, Salles G, et al. Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. *Blood*. 2006; 108(1): 278-285. doi: 10.1182/blood-2005-04-1567.
27. Gemmati D, Ongaro A, Scapoli GL, Della Porta M, Tognazzo S, Serino ML, et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. *Cancer Epidemiol Biomarkers Prev*. 2004; 13(15): 787-794.
28. De Re V, Cannizzaro R, Canzonieri V, Cecchin E, Caggiari L, De Mattia E, et al. MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer. *Tumour Biol*. 2010; 31(1): 23-32. doi: 10.1007/s13277-009-0004-1.
29. Berglund M, Enblad G, Turesson I, Edman V, Thunberg U. Folate-Metabolizing Genes in Lymphoma Patients from Sweden. *Scand J Immunol*. 2009; 70(4): 408-410. doi: 10.1111/j.1365-3083.2009.02287.x.
30. Kim JK, Kim S, Han JH, Kim HJ, Chong SY, Hong SP, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population. *Anticancer Res*. 2005; 25(3B): 2249-2252.
31. Weiner AS, Beresina OV, Voronina EN, Voropaeva EN, Boyarskih UA, Pospelova TI, et al. Polymorphisms in folate-metabolizing genes and risk of non-Hodgkin's lymphoma. *Leuk Res*. 2011; 35(4): 508-515. doi: 10.1016/j.leukres.2010.10.004.